Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06173518 · ClinicalTrials.gov registry record · Phase 1

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

A Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by Autolus Limited.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
8
Study locations

NCT06173518: Recruiting Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by Autolus Limited.

NCT06173518 is a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Autolus Limited. The registered enrollment target is 30 participants, above the 24-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (25% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06173518, a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Autolus Limited.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
8
Study locations

Study Summary

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).

Conditions Studied

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Interventions

  • BIOLOGICAL AUTO1

Study Locations (8)

Other

  • Hospital Vall d'Hebron - Barcelona
  • Hospital Nino Jesus - Madrid
  • Great Ormond Street Hospital for Children NHS Foundation Trust - London
  • Royal Manchester Children's Hospital - Manchester
  • Great North Children's Hospital - Newcastle upon Tyne

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Texas

  • Methodist Children's Hospital - San Antonio

Utah

  • Primary Children's Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-11-16
Est. Completion 2027-11
Phase Phase 1
Autolus Limited

5 total trials

What NCT06173518 shows while recruiting

NCT06173518 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, above the 24-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (25% higher).

The record links to 2 conditions, with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AUTO1 is the first listed.

NCT06173518 lists 8 locations in 4 states (Other, Pennsylvania, Texas).

Frequently Asked Questions

What is clinical trial NCT06173518 about?

NCT06173518 is a clinical study titled "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)". This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Ho...

What is the current status of trial NCT06173518?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-16. Estimated completion is 2027-11.

What conditions does trial NCT06173518 study?

This clinical trial studies the following conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.

What interventions are being tested in trial NCT06173518?

The interventions under investigation include: AUTO1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06173518?

This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06173518 being conducted?

This trial has 8 study locations across Pennsylvania, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06173518

Source: ClinicalTrials.gov NCT06173518, the US trial registry maintained by the National Library of Medicine. NCT06173518 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.